NORWOOD, MA -- (Marketwire) -- 07/15/09 -- Infinata, Inc., a division of Pearson PLC (NYSE: PSO), has announced being named to CIO Magazine's 'Vendors Most Important to Winners' Success List 2009' for its development of a custom private labeling information portal for one of the world's largest investment management firms.

The solution has helped Infinata's client utilize information to drive new sales and increase customer retention. Completely custom-built, the application was designed to leverage Infinata's proprietary data on high net worth individuals and plan sponsors, including foundations and endowments.

"This award is another good example of how our custom, information-based solutions have a dramatic impact on how our customers use information to increase their productivity and success," said Jason Krantz, Chief Executive Officer, Infinata, Inc.

Infinata is the leading expert in developing and hosting custom private label information portals. These portals help clients leverage information to optimize their business intelligence and marketing functions. The solutions include: customized analytics, email alert systems, and implementation of third party reporting platforms.

"We thank CIO magazine and our investment management and bank clients worldwide for this prestigious distinction," said Jason Krantz, Chief Executive Officer, Infinata, Inc.

About Infinata

Infinata is a wholly owned subsidiary of the Financial Times Group, publisher of the Financial Times newspaper and FT.com. FT Group is a division of Pearson PLC (NYSE: PSO), the international media group.

Infinata is an innovative provider of information solutions and marketing analytics to the global financial service and life science industries. The firm provides its clients with propriety information as well as customized solutions to help them utilize their own information to improve their business intelligence function. Infinata's proprietary information assets include intelligence and research on high net worth individuals & plan sponsors and on the pharmaceutical industry.

For more information, write to or visit: www.infinata.com